← Back to Search

Genomic Therapy

Acute Lymphobastic Leukemia (ALL) Treatment Options for Acute Lymphoblastic Leukemia

N/A
Waitlist Available
Led By Jodi Mayfield, MD
Research Sponsored by New Mexico Cancer Care Alliance
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 years
Awards & highlights

Study Summary

This trial will screen newly diagnosed ALL patients for genomic mutations and then enroll them in available clinical trials that target those mutations.

Eligible Conditions
  • Acute Lymphoblastic Leukemia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
ALL characterization: Low Density Array
ALL characterization: Next Generation Sequencing
ALL characterization: SNP analysis
Secondary outcome measures
Feasibility of discovering molecular features in ALL with therapeutic relevance
Neoplasm, Residual
Relationship between race/ethnicity and outcome
+1 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Genomic TestingExperimental Treatment1 Intervention
Newly diagnosed ALL patients will undergo genomic studies listed in Primary Objective 1. Analyses will be performed on a bone marrow (BM) aspirate at initial diagnosis (patients with an absolute blast count of at least 1,000/μL, may submit 2 mL of peripheral blood at diagnosis for each 1 mL of required BM. In patients in whom the aspirate cannot be obtained, a core biopsy will be used). In addition, flow cytometric analysis and deep sequencing will be used to characterize and monitor the molecular heterogeneity and clonal evolution of disease during front-line therapy. BM, blood, and buccal specimens will be collected on day 29 of induction treatment and possibly at a later time point if relapse occurs.

Find a Location

Who is running the clinical trial?

New Mexico Cancer Care AllianceLead Sponsor
70 Previous Clinical Trials
52,446 Total Patients Enrolled
Jodi Mayfield, MDPrincipal InvestigatorUniversity of New Mexico, Department of Pediatrics

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Acute Lymphoblastic Leukemia Therapies Informed by Genomic Analyses
2016. "Acute Lymphoblastic Leukemia Therapies Informed by Genomic Analyses". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02580981.
~2 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top